Digoxin and spironolactone can be prescribed together, but the combination is classified as a major interaction that requires close medical monitoring. Spironolactone increases the half-life of digoxin, meaning the body takes longer to eliminate it, which can lead to higher digoxin levels in the blood and an increased risk of digitalis toxicity. If you are taking both medications, your doctor and pharmacist need to know, and your digoxin levels may need to be monitored more carefully than usual.
According to records compiled from U.S. FDA drug labeling and clinical reference data, this interaction is classified as major in severity. The documented interaction is described as follows: Spironolactone increases half-life of digoxin, resulting in increased serum levels and potential digitalis toxicity.
The mechanism of this interaction—the biological reason it occurs—is documented as increased digoxin half-life. This means that when spironolactone is present in the body, it slows down the rate at which digoxin is eliminated, allowing digoxin to accumulate over time.
To understand what this interaction means in practical terms, it helps to know what digoxin does and what digoxin levels have to do with safety.
Digoxin and the therapeutic window: Digoxin is a cardiac glycoside used to treat heart failure and certain irregular heart rhythms. It works by strengthening the heart muscle's contractions and slowing the heart rate. However, digoxin has a narrow therapeutic window—the range between an effective dose and a toxic dose is relatively small. When digoxin levels are too low, the medication is not effective; when they are too high, they cause serious adverse effects.
What "half-life" means: The half-life of a drug is the time it takes the body to eliminate half of the dose from the bloodstream. If digoxin normally has a half-life of about 30–40 hours, that means that if you take a dose, half of it will be gone in that time frame, and the remaining half will be gone in another 30–40 hours, and so on. If spironolactone increases this half-life, digoxin stays in your body longer, and more of it accumulates with each dose.
The accumulation problem: When you take digoxin regularly (as is typical for heart conditions), your body reaches a steady state—a balance between the amount you take in and the amount your body eliminates. If the elimination rate slows down because of spironolactone, the steady-state level of digoxin in your blood can rise. Over days or weeks, this can push digoxin levels above the therapeutic range.
Digitalis toxicity: Digitalis toxicity occurs when digoxin levels become too high. Symptoms can include nausea, vomiting, loss of appetite, fatigue, dizziness, and changes in heart rhythm (including dangerous irregular heartbeats). In severe cases, digitalis toxicity can be life-threatening. The source record identifies this risk explicitly as a potential consequence of the spironolactone–digoxin interaction.
Why spironolactone affects digoxin elimination: The source record documents that spironolactone increases digoxin's half-life but does not specify the underlying mechanism—that is, the precise biological process by which spironolactone causes this change. General background knowledge suggests that certain drugs can affect how the kidneys filter and reabsorb medications, and spironolactone's effects on kidney function and electrolyte balance may play a role, but the source record itself does not detail this. What matters clinically is the documented fact: when these two drugs are used together, digoxin accumulates and toxicity risk rises.
Because this is a major interaction affecting a drug with a narrow therapeutic window, anyone taking both digoxin and spironolactone should have this combination reviewed by their healthcare provider and pharmacist. The interaction applies to all patients on both medications, not just a specific subgroup.
People with reduced kidney function may be at higher risk overall for digoxin accumulation (since the kidneys eliminate digoxin), and the addition of spironolactone could amplify that risk. Similarly, elderly patients, who often have reduced kidney function and take digoxin for heart failure, warrant especially careful monitoring. However, the source record for this specific interaction does not identify particular risk groups—the interaction itself is what drives the need for attention.
Consider a patient with heart failure taking a stable dose of digoxin—say, 0.25 mg daily—whose levels are being monitored and are within the therapeutic range. The patient's cardiologist then prescribes spironolactone for its beneficial effects on heart failure. Initially, the patient feels fine, but over the course of two to three weeks, the rate at which the body eliminates digoxin slows. The amount of digoxin in the bloodstream climbs, even though the patient is taking the same dose. At some point, the patient develops nausea, loss of appetite, and a sensation of palpitations. A serum digoxin level drawn at this time reveals that the concentration has risen into the toxic range. This scenario illustrates why monitoring is essential when both medications are started or continued together.
In another hypothetical case, a patient has been stable on both digoxin and spironolactone for months with regular digoxin monitoring. If kidney function declines (for example, due to aging or a new condition), the already-slowed elimination of digoxin could slow further, pushing levels upward again. This shows why ongoing monitoring remains important, not just at the time the drugs are first combined.
If you are taking or considering both digoxin and spironolactone, bring up the following points with your healthcare team:
If you are taking both digoxin and spironolactone, or if you are considering starting either medication while on the other, use checkdruginteractions.com to review your complete medication profile and identify all potential interactions. Then confirm your medication plan—including any monitoring schedule, dose adjustments, and warning signs to watch for—with your pharmacist or physician. Do not start, stop, skip, or change any dose on your own. Your healthcare team can help you weigh the benefits of both medications against the interaction risk and ensure you receive safe, effective treatment.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Furosemide is contraindicated with lithium due to reduced renal clearance and high toxicity risk. Learn why and what to discuss with your...
Fluconazole may increase phenytoin levels via CYP2C9 inhibition. Understand the documented interaction and why monitoring is recommended.
A major documented interaction between omeprazole and methotrexate can elevate methotrexate levels. Learn what the evidence shows and wha...